CN103796640A - 适于治疗或预防结核的脂质体制剂 - Google Patents

适于治疗或预防结核的脂质体制剂 Download PDF

Info

Publication number
CN103796640A
CN103796640A CN201280011787.0A CN201280011787A CN103796640A CN 103796640 A CN103796640 A CN 103796640A CN 201280011787 A CN201280011787 A CN 201280011787A CN 103796640 A CN103796640 A CN 103796640A
Authority
CN
China
Prior art keywords
liposomal formulation
tuberculosis
liposome
suspension
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280011787.0A
Other languages
English (en)
Chinese (zh)
Inventor
佩尔·乔娜·卡唐娜·伊杰勒塞斯
伊莎贝尔·艾玛特·里拉
布兰卡·雷耶斯
艾瑞德纳·瑟格
梅尔斯·艾玛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archivel Farma SL
Original Assignee
Archivel Farma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11150072A external-priority patent/EP2471511A1/en
Application filed by Archivel Farma SL filed Critical Archivel Farma SL
Priority to CN201710129725.4A priority Critical patent/CN107296793A/zh
Publication of CN103796640A publication Critical patent/CN103796640A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280011787.0A 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂 Pending CN103796640A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710129725.4A CN107296793A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11150072.4 2011-01-04
EP11150072A EP2471511A1 (en) 2011-01-04 2011-01-04 Liposome formulation suitable for treating or preventing tuberculosis
EP11183487 2011-09-30
EP11183487.5 2011-09-30
PCT/EP2012/050080 WO2012093137A1 (en) 2011-01-04 2012-01-04 Liposome formulation suitable for treating or preventing tuberculosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710129725.4A Division CN107296793A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Publications (1)

Publication Number Publication Date
CN103796640A true CN103796640A (zh) 2014-05-14

Family

ID=45509459

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280011787.0A Pending CN103796640A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂
CN201710129725.4A Pending CN107296793A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710129725.4A Pending CN107296793A (zh) 2011-01-04 2012-01-04 适于治疗或预防结核的脂质体制剂

Country Status (18)

Country Link
US (1) US9877917B2 (enExample)
EP (1) EP2661253B1 (enExample)
JP (1) JP6096675B2 (enExample)
KR (1) KR101820026B1 (enExample)
CN (2) CN103796640A (enExample)
BR (1) BR112013017267B1 (enExample)
CA (1) CA2823747C (enExample)
CO (1) CO6801728A2 (enExample)
ES (1) ES2631556T3 (enExample)
HU (1) HUE032409T2 (enExample)
IL (1) IL227338B (enExample)
LT (1) LT2661253T (enExample)
MX (1) MX341918B (enExample)
PL (1) PL2661253T3 (enExample)
RU (1) RU2648842C2 (enExample)
SI (1) SI2661253T1 (enExample)
WO (1) WO2012093137A1 (enExample)
ZA (1) ZA201305697B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110891595A (zh) * 2017-05-12 2020-03-17 葛兰素史密丝克莱恩生物有限公司 干燥的组合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法，及其制备的可变性脂质体
JP2016163851A (ja) * 2015-03-06 2016-09-08 国立大学法人福井大学 コンポジット型可溶化ナノリポソーム及びその製造方法
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения
CN109675059A (zh) * 2019-01-23 2019-04-26 青岛大学 一种类杆菌脂质体及其制备方法与应用
US11202823B2 (en) * 2019-04-05 2021-12-21 Northwestern University Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses
CN120456894A (zh) * 2021-10-14 2025-08-08 爱琴韦尔制药公司 用于治疗活动性结核病的脂质体制剂
CN115850520A (zh) * 2022-12-12 2023-03-28 中国农业大学 新型结核病亚单位疫苗al的制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874785A (zh) * 2003-10-31 2006-12-06 爱琴韦尔制药公司 用于与其它药物一起联合治疗结核的免疫治疗剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) * 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
BR0103887C1 (pt) * 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
CN101283085A (zh) * 2005-08-11 2008-10-08 哈佛大学的校长及成员们 用于干燥细胞形式的方法和组合物
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20090081284A1 (en) 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
BRPI0705630F8 (pt) * 2007-12-12 2022-01-18 Univ Estadual Campinas Unicamp Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
SG190937A1 (en) * 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874785A (zh) * 2003-10-31 2006-12-06 爱琴韦尔制药公司 用于与其它药物一起联合治疗结核的免疫治疗剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张静等: "脂质体的液晶态结构和稳定性研究", 《液晶与显示》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110891595A (zh) * 2017-05-12 2020-03-17 葛兰素史密丝克莱恩生物有限公司 干燥的组合物

Also Published As

Publication number Publication date
MX341918B (es) 2016-09-07
IL227338A0 (en) 2013-09-30
ZA201305697B (en) 2014-07-30
ES2631556T3 (es) 2017-09-01
RU2648842C2 (ru) 2018-03-28
MX2013007855A (es) 2013-10-25
PL2661253T3 (pl) 2017-08-31
US20150050327A1 (en) 2015-02-19
JP2014501768A (ja) 2014-01-23
HUE032409T2 (en) 2017-09-28
SI2661253T1 (sl) 2017-07-31
EP2661253A1 (en) 2013-11-13
RU2013136379A (ru) 2015-02-10
CA2823747A1 (en) 2012-07-12
IL227338B (en) 2019-01-31
CN107296793A (zh) 2017-10-27
US9877917B2 (en) 2018-01-30
BR112013017267A2 (pt) 2018-01-09
CA2823747C (en) 2019-07-23
WO2012093137A9 (en) 2012-12-27
EP2661253B1 (en) 2017-04-19
LT2661253T (lt) 2017-05-25
KR20140021538A (ko) 2014-02-20
JP6096675B2 (ja) 2017-03-15
BR112013017267B1 (pt) 2021-06-22
CO6801728A2 (es) 2013-11-29
BR112013017267A8 (pt) 2018-11-06
KR101820026B1 (ko) 2018-01-18
WO2012093137A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
JP6096675B2 (ja) 結核の治療又は予防に適切なリポソーム製剤
JP5713672B2 (ja) 結核のワクチンおよびその使用方法
ES2853773T3 (es) Procedimientos novedosos para inducir una respuesta inmune
RU2526910C2 (ru) Профилактическая вакцина от туберкулеза
US8795719B2 (en) Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
US20260137766A1 (en) Liposome formulations for treatment of active tuberculosis
CN104411326B (zh) 抗哮喘的mtb‑c疫苗
Trentini et al. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection
EP2471511A1 (en) Liposome formulation suitable for treating or preventing tuberculosis
HK1171659A (en) Liposome formulation suitable for treating or preventing tuberculosis
EA053229B1 (ru) Применение липосомных композиций для лечения активной формы туберкулеза
WO2025191183A1 (en) Liposome formulations for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140514